Acute Myeloid Leukemia Clinical Trial
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
Summary
This study will examine the safety and anti-leukemic profile of SGN-CD33A (vadastuximab talirine) in patients with relapsed chemo-resistant AML, who are given vadastuximab talirine in sequence with standard treatments before a planned stem cell transplant, or as maintenance therapy after a stem cell transplant. The main purpose of the study is to find the best dose and determine the anti-leukemic activity of vadastuximab talirine, given either pre- or post-allogeneic stem cell transplant (alloSCT) for adults with relapsed or refractory AML. This will be determined by assessing the safety and tolerability of vadastuximab talirine. In addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will be assessed.
Eligibility Criteria
Inclusion Criteria:
Relapsed/refractory acute myeloid leukemia (AML) except for acute promyelocytic leukemia
Eastern Cooperative Oncology Group status of 0 or 1
Adequate baseline renal and hepatic function
For Pre-allo Part A (before stem cell transplant): Relapsed or refractory AML (greater than 5% blasts)
For Pre-allo Part A (before stem cell transplant): Availability of an HLA matched related or unrelated donor
For Pre-allo Part A (before stem cell transplant): Eligible for an allogeneic hematopoietic stem cell transplant
For Post-allo Part B: Transplant must have been performed with active AML (greater than 5% blasts) using a conventional conditioning regimen and have achieved CR or CRi post-alloSCT (with ANC greater than or equal to 1,000 and platelet greater than or equal to 50,000)
For Post-allo Part B: Treatment must begin at least 42 days, but no more than 100 days post-transplant.
Exclusion Criteria:
Inadequate heart function
Inadequate lung function
Previous central nervous system leukemia
Any history of another metastatic malignancy
Anti-leukemia treatment within14 days of study drug (other than hydroxyurea or 6-mercaptopurine), immunosuppressive therapy (except for GVHD treatment/prophylaxis in Part B), or investigational agents
For Pre-allo Part A (before stem cell transplant): Partially matched donors (related or unrelated) and umbilical cord blood cells are excluded as the source of hematopoietic stem cells
For Pre-allo Part A (before stem cell transplant): Prior alloSCT
For Post-allo Part B: Active GVHD Grade 2 or higher
For Post-allo Part B:History of veno-occlusive disease requiring defibrotide
For Post-allo Part B: History of Grade 2 or higher hepatic GVHD
For Post-allo Part B: Concurrent use of corticosteroids equivalent of prednisone at a dose of greater than 0.5 mg/kg
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 11 Locations for this study
Duarte California, 91010, United States
Denver Colorado, 80218, United States
Tampa Florida, 33612, United States
Chicago Illinois, 60637, United States
Westwood Kansas, Unite, United States
Boston Massachusetts, 02215, United States
New York New York, 10021, United States
New York New York, 10065, United States
Cleveland Ohio, 44106, United States
Houston Texas, 77030, United States
Seattle Washington, 98109, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.